November 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
April 2024 in “Liječnički vjesnik” Modern treatments can effectively regrow hair and improve life for people with alopecia areata.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
11 citations
,
November 2015 in “Experimental Dermatology” The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
January 2024 in “Indian Journal of Paediatric Dermatology” A rare case links early-onset alopecia universalis and nephrotic syndrome, suggesting genetic immune issues.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
2 citations
,
January 2023 in “Pharmaceuticals” Natural products and phytochemicals may help with hair regrowth, but more research is needed.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
2 citations
,
February 2024 in “Indian Dermatology Online Journal” Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
August 2025 in “Australasian Journal of Dermatology” Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
June 2024 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Particulate matter causes inflammation in hair cells, potentially harming hair growth.
December 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
November 2022 in “Journal of Investigative Dermatology” The lotion with specific plant extracts effectively increased hair growth and improved hair cycle in subjects after 3 months.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
December 2021 in “Figshare” New therapies like JAK inhibitors and stem cells show promise for treating vitiligo.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.